Article
Braf V600E mutation in melanoma: translational current scenario.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Sept 2016
Guadarrama-Orozco J A, Ortega-Gómez A, Ruiz-García E B, Astudillo-de la Vega H, Meneses-García A, Lopez-Camarillo C
Abstract excerpt
Melanoma was one of the translational cancer examples in clinic, including target therapy related to specific biomarkers impacting in the outcome of melanoma patients. Melanomagenesis involved a wide variety of mutations during his evolution; many of these mutated proteins have a kinase activity. One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.